TÜBİTAK 1001 project titled "Investigation Of Effectiveness of Tepotinib-Temozolomide Combination in iPSC-Derived Cerebral Organoids by Mimicking Stage Four Glioblastoma Multiforme-Like Cancer Model in 3D Environment" was written in collaboration with Öykü Gönül Geyik, who works at our Faculty of Medicine, Remzi Okan Akar, and Kaan Adacan, who works at the Molecular Cancer and Research Center of Istinye University, under the direction of Hakan Darıcı, who works at our Faculty of Medicine was accepted.
In this project, cerebral organoids will be generated in a 3D environment and their relationship with glioblastoma cells will be examined. The glioblastoma cells intended for use will have clinically significant expression of EGFRvIII, and the response to the FDA-approved c-MET inhibitor and the widely used Temozolomide will be evaluated.